Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide
Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-15
Target enrollment:
Participant gender:
Summary
This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD) and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.
Phase:
PHASE4
Details
Lead Sponsor:
Stanford University
Treatments:
Absorptiometry, Photon Glucose Tolerance Test Pioglitazone Proton Magnetic Resonance Spectroscopy Tirzepatide